PRODUCT MONOGRAPH. HAVRIX hepatitis A vaccine, inactivated. Suspension This leaflet is part III of a three-part “Product Monograph”. HAVRIX, hepatitis A vaccine, is a sterile suspension containing formaldehyde – has resulted from the administration of any vaccine product. Havrix (Hepatitis A Vaccine, Inactivated) is a noninfectious hepatitis A vaccine .. NDC Package of 1 Prefilled Disposable Tip-Lokâ Syringe.
|Published (Last):||20 April 2012|
|PDF File Size:||7.96 Mb|
|ePub File Size:||9.46 Mb|
|Price:||Free* [*Free Regsitration Required]|
During the course of natural infection with the hepatitis A virus, the initial antibody response is predominantly of the IgM class. With through agitation, Harvix is a homogenous, turbid white suspension, and Vaqta ijsert a slightly opaque, white suspension. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following inset of the vaccine [see Contraindications 4 ].
General Disorders and Administration Site Conditions: Medically reviewed on Jan 1, Outbreak Setting and a Field Efficacy Trial: Find out more here. Also, Havrix has been packge to be efficacious in a clinical study of children at high risk of HAV infection [see Clinical Studies Havrix Monodose must not be mixed with other vaccines in the same syringe. Group 1 Havrix coadministered with pneumococcal 7-valent conjugate vaccine Wyeth Pharmaceuticals Inc.
Adults at least 40 years, immunosuppressed patients, or those with chronic liver disease planning to depart in 2 weeks or less should receive an initial dose of the vaccine plus immune globulin 0.
Havrix (hepatitis A vaccine) dose, indications, adverse effects, interactions from
The vaccine should be given only if the potential benefits clearly outweigh the risk of administration. After agitation, the injection should appear as an opaque, white, homogenous suspension. Treatment of this lysate with formalin ensures viral inactivation. Immunocompromised persons may have a diminished immune response to Havrix, including individuals receiving immunosuppressant therapy. The health care professional should have immediate availability of epinephrine 1: Havrix may not prevent hepatitis A infection in individuals who have an unrecognized hepatitis A infection at the time of vaccination.
A booster dose can be given at least 6 months after the first dose to complete the series. Vaccine response rates were similar among the 3 age groups that received Havrix. Increasing the dose of viral antigen directly affects the speed at which seroconversion occurs. One type of prefilled syringe has a tip cap which may contain natural rubber latex.
The IgG antibodies remain detectable indefinitely. Health havric professionals administering vaccines should take appropriate precautions to prevent allergic reactions in vaccine recipients. The observed reduction in hepatitis A incidence in the general population vaccinated and non-vaccinated in both countries are consistent with herd immunity.
To email a medicine you must sign up and log in. Incorrect administration may result in inadequate immunity. Havrix contains the following excipients: Havrix is available in vials and 2 types of prefilled syringes. The manufacturer recommends caution when administering to nursing mothers; however according to the Advisory Committee on Immunization Practices ACIPinactivated vaccines pose no risk to breast-feeding mothers or imsert infants.
Havrix Monodose Vaccine
A separate syringe and needle should be used for each person receiving hepatitis A vaccine, inactivated. Shake vigorously just prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
In order to ensure long term protection, a booster dose should be given between 6 and 12 months after the primary dose. According to a published article, storage of Havrix GlaxoSmithKline at room temperature for up to 72 hours is acceptable, and Vaqta Merck can be stored at 37 degrees C For example immunisation should be considered for the following risk groups:. Do not mix Havrix with any other vaccine or product in the same packaeg or vial.
Immunization against hepatitis A virus in persons at risk; products utilize inactivated whole virus propagated in MRC5 human diploid cells.
Subjects with chronic liver disease had a lower antibody response to Havrix than healthy subjects [see Clinical Studies Packaage example immunisation should be considered for the following risk groups: Angioedema, erythema multiforme, hyperhidrosis. Havrix Hepatitis A Vaccine is a sterile suspension of inactivated virus for intramuscular administration. Immunisation should be postponed in subjects suffering from an acute severed febrile illness. Subscribe to free Drugs.
The vial stopper of Havrix does not contain latex. Injection site reaction, such as swelling or induration uncommon with Havrix Junior Monodose formulation. Safety data were obtained from 2 ineert sources in which large populations were vaccinated. A decision must be made whether to discontinue breast-feeding or to abstain from vaccination taking into account the benefit of breast feeding for the child and the benefit of vaccination for the woman. Available for Android and iOS devices. Solicited local adverse events were reported as follows among children who received the first dose of Havrix coadministered with pneumococcal 7-valent conjugate vaccine: Impact of mass vaccination on disease incidence A reduction in the incidence of hepatitis A was observed in countries where a two-dose Havrix immunization programme was implemented for children in their second year of life: